If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
102
results.
Updated on
20/08/2026 [07:13:00]
Results 50 to 75 of 102
Absstract of: WO2026151301A1
The present invention provides an aqueous solution composition capable of rapidly preventing, alleviating or eliminating symptoms of acute respiratory diseases by applying a hypertonic aqueous solution composition containing molecular iodine to all parts of the eyes, oral cavity, nasal cavity, and respiratory tract. The present invention provides a hypertonic aqueous solution composition containing molecular iodine, which can prevent and eliminate acute respiratory infectious diseases such as cold, flu, and COVID-19, and can rapidly alleviate or eliminate runny nose and nasal congestion caused by allergic and non-allergic rhinitis.
Absstract of: US20260201021A1
0000 Disclosed is a Fv-antibody having a specific binding ability to a cleavage site of a SARS-COV-2 spike protein by TMPRSS2. The Fv-antibody includes a peptide sequence of DPPPPAVAADV or CRDLLGVVRDF.
Absstract of: WO2026151918A1
Described herein are compositions and methods of using the same. The compositions can include a first nucleic acid encoding for an HPV E6 peptide or a variant or fragment thereof; a second nucleic acid encoding for an HPV E7 peptide or a variant or fragment thereof; and a third nucleic acid encoding a subdomain of the SARS-CoV-2 spike protein.
Absstract of: US20260201414A1
The present invention provides a method for producing coronavirus virus-like particles (VLPs) and a vaccine comprising the same. The method comprises: constructing a recombinant baculovirus carrying a coronavirus spike protein gene; transducing mosquito cells with the recombinant virus; and culturing the transduced cells in a serum-free medium to produce VLPs containing the coronavirus spike protein. Preferably, the mosquito cells are C6/36 cells, and the spike protein gene may be derived from SARS-COV, MERS-COV, or SARS-COV-2. Furthermore, the invention provides a vaccine containing the VLPs produced by the above method, which can be administered intranasally or by intramuscular injection.
Absstract of: AU2026205187A1
COMBINED PLANT COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS INCLUDING COVID-19 Abstract The present invention is directed to a compound herbal composition when used in treating COVID-19, comprising: Radix angelicae dahuricae; Herba moslae; Flos lonicerae japoni- cae; Semen sojae preparatum; Fructus momordicae; Rhizoma zingiberis recens; Radix platycodonis; Rhizoma phragmitis; Rhizoma imperatae; Fistular onion stalk; Radix et rhizome glycyrhizae; Fructus evodiae; Fructus alpiniae oxyphyllae; Fructus psoraleae; Fructus corni; Flower of Hyacinth Bean; Semen cuicis; and optionally together with up to about 1 wt% of one or more pharmaceutically acceptable excipients. COMBINED PLANT COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS INCLUDING COVID-19 un - u n b s t r a c t
Absstract of: EP4775268A2
The invention relates to an anti-coronavirus polypeptide as well as derivatives and application thereof, provides the anti-coronavirus polypeptide, and provides cholesterol-containing derivatives of the polypeptide on the basis of the anti-coronavirus polypeptide. Particularly, the original strain and the variant strain of the SARS-CoV-2 have an unexpected inhibition effect, can be used for preparing medicines or vaccines for preventing or treating the new coronavirus, and have great prevention or treatment potential.
Absstract of: KR20260109386A
본 발명은 RGS2 및 SPL의 발현 수준을 측정할 수 있는 제제를 포함하는 SARS-CoV-2 감염증 중증도 진단용 조성물에 관한 것이다. 본 발명의 SARS-CoV-2 감염증 환자의 중증도 진단용 조성물을 이용하는 경우, 고혈압을 앓고 있는 SARS-CoV-2 감염증 환자의 중증질환 진행 여부에 대해 진단하는 데 사용될 수 있다.
Absstract of: US20260193343A1
The present invention relates to an antiviral composition comprising Natural Killer (NK) cells as an active ingredient and, more particularly, to a composition for preventing or treating COVID-19 virus (SARS-COV-2) infection comprising NK cells as an active ingredient and a method for culturing lymphocytes comprising anti-COVID-19 virus NK cells.
Absstract of: US20260193327A1
0000 The invention is in the field of medical treatment, and relates to a method for treating SARS-CoV-2 infections. In particular, the present invention relates to methods for prophylactic and/or therapeutic treatment of betacoronavirus infections, in particular, SARS-CoV-2 infections by means of intranasal administration or oral inhalation of antibodies.
Absstract of: US20260196317A1
A system and method that enables users to provide authenticated medical records (e.g., vaccination records, viral anti-body test results, etc.) to a third-party (e.g., a venue) to gain access to the third-party is provided. In this way, the third party may confirm that the user is sufficiently immune to a particular disease (e.g., COVID-19) and may thereby minimize the threat of the user introducing the contagious disease to the third party. The system includes a biometric data recognition system that authenticates the identity of a user, a medical records acquisition system that acquires the medical records of the authenticated user, and a system for the displaying or otherwise providing the medical records to the third-party for review. The system also includes a system identification card that includes the user's contact information, alphanumeric characters associated with the user's driver's license number, medical records of the user, and other elements.
Absstract of: US20260193724A1
0000 A method for the detection of SARS-CoV-2 in a sample based on reverse transcription loop-mediated isothermal amplification (RT-LAMP) of a target nucleic acid sequence. The RT-LAMP amplicons are detected by gold nanoparticles (AuNPs) functionalized with a probe specific for regions of the target sequence. Kits for the detection of SARS-CoV-2 in a sample are also provided wherein the kit comprises a reverse transcriptase, a polymerase, a primer set for reverse transcription loop-mediated isothermal amplification (RT-LAMP) of the target sequence in a SARS-CoV nucleic acid sequence and variants thereof, and a conjugated nanoparticle solution comprising gold, water, and a probe sequence that is at least 85% identical to SEQ ID No.: 1.
Absstract of: WO2026148343A1
Compositions and methods for protecting against a wide spectrum of viral and bacterial infections, including Covid-19, and for treating established infection and infectious inflammation are described. The composition includes a novel combination of vitamins, minerals, nutraceuticals, and phytochemicals, which may be compounded as a pill, tablet, powder, capsule or liquid to be taken orally or via other administration routs one or more times per day, to serve as immune boosters, antibacterial agents, and antiviral agents along with providing anti-inflammatory effects in humans and animals.
Absstract of: US20260193700A1
The invention describes a kit for detection of a target polynucleotide using a CRISPR effector system that comprises CAS9 from Francisella novicida, a synthetic sgRNA and a detection scheme based on binding and subsequent enzymatic cleavage of the target polynucleotide. The invention also describes a method for detection of a target polynucleotide using the kit. The kit can be applied to both pathogenic and non-pathogenic polynucleotides and can be used to distinguish polynucleotides different by a single mismatch without the need for sequencing. The kit can also be used for detection of COVID-19. The kit is economical, easy to assemble and provides a robust and rapid readout that can be appropriately adapted for point of care applications.
Absstract of: WO2026148353A1
Provided are methods of suppressing an anti-oncolytic virus (anti-OV) antibody response to an oncolytic virus (OV) therapy. The methods comprise administering a B cell-depleting agent to a subject (e.g., a human subject) prior to and/or concurrently with administration of a therapeutic OV to the subject. Non-limiting examples of B cell-depleting agents include those that target CD19 or CD20. In some instances, a B cell-depleting agent comprises or consists of an antibody. In certain embodiments, the therapeutic OV administered to the subject is from the family Poxviridae, Herpesviridae, Adenoviridae, Paramyxoviridae, Rhabdoviridae, Reoviridae, Picornaviridae, Parvoviridae, or Coronaviridae. According to some embodiments, the B cell-depleting agent is administered (e.g., only administered) prior to and/or concurrently with an initial administration of the therapeutic OV to the subject. OV therapies of interest include, but are not limited to, OV cancer therapies.
Absstract of: WO2026147882A1
The present invention is generally directed to a potent therapy for SARS-CoV-2 (CoV2) disease using pharmaceutical composition disclosed herein. Provided a new combinatorial drag or a new pharmaceutical composition comprising compound of Formula (II-I-W-B), and their use for the treatment or prevention of coronavirus infections, particularly the use for the treatment or prevention of infections caused by SARS-CoV-2 and mutants thereof.
Absstract of: EP4772515A1
The present invention belongs to the field of pharmaceutical technology and relates to a salt of a cyclic carbonate nucleoside compound, its crystal forms, preparation methods, and applications. The salt of the cyclic carbonate nucleoside compound has the structure shown in Formula I. When Y is hydrobromic acid and n=1, the salt of this nucleoside compound exists as Crystal Form A or Crystal Form B. Crystal Form A has advantages such as good physical and chemical stability, good solid properties, good water solubility, low hygroscopicity, and high oral bioavailability. It can be used to prepare drugs for treating and/or alleviating related diseases caused by viruses (particularly novel coronavirus, feline infectious peritonitis virus, respiratory syncytial virus, porcine epidemic diarrhea virus, feline calicivirus, etc.).
Absstract of: KR20260104317A
본 발명은 SARS-CoV-2 mRNA 백신 접종에 의해 발생되는 대상체의 부작용 예후 예측용 조성물 및 이를 포함하는 키트 및 SARS-CoV-2 mRNA 백신 스크리닝용 조성물에 관한 것이다. 구체적으로, 본 발명은 비만 또는 당뇨병 환자에서 SARS-CoV-2 mRNA 백신 접종으로 인한 부작용과 GSTP1 유전자가 연관이 높음을 확인하고, 이를 이용하여 SARS-CoV-2 mRNA 백신 접종에 의해 발생되는 대상체의 부작용 예후 예측용 조성물 또는 SARS-CoV-2 mRNA 백신 스크리닝용 조성물을 제공하고자 한다.
Absstract of: EP3913069A1
0001 The invention relates to a diagnostic kit for multiple detection of 4 viruses of the Family Coronaviridae: HCoV, SARS-CoV, MERS-CoV and the SARS-CoV-2 viral strain that has caused a pandemic of the disease known as COVID-19. The kit uses a "One-Step" approach with quantitative gene amplification after backward transcription of the viral genome (rRT-PCR). 0002 In order to avoid potential false negatives, the invention contains a double control using Porcine Epidemic Diarrhoea Virus (PEDV -CoV) and Ribonuclease P (RNase P-RP).
Absstract of: CN122341390A
The present disclosure relates to methods of treating diseases and/or conditions associated with Covid-19 infection, including growing new crowns, comprising administering a COX-2 inhibitor, an antiviral compound, and one or more additional active ingredients, such as a combination of nemategravir and ritonavir, Monoravir, a BCG vaccine, or ivermectin.
Absstract of: CN122326822A
The invention provides a method for regulating and controlling invasion of SARS-CoV-2 pseudovirus into alveolar epithelial cells by mechanical drawing force. Comprising the following steps: screening SARS-CoV-2 pseudovirus infection titer capable of meeting infection efficiency; s2, taking the SARS-CoV-2 pseudovirus of which the titer is screened in the step S1, infecting alveolar epithelial cells (ATII cells) in the bionic microfluidic alveolar cell chip, meanwhile, applying gradient circulating mechanical drawing force to the bionic microfluidic alveolar cell chip, and monitoring the infection efficiency of the SARS-CoV-2 pseudovirus by using immunofluorescent staining, establishing a relation model of the mechanical drawing force and the infection efficiency; the mechanical drawing force is adjusted based on a relation model of the mechanical drawing force and the infection efficiency, so that the infection efficiency of the SARS-CoV-2 pseudovirus in the bionic microfluidic pulmonary alveolar cell chip is adjusted. The research reveals that the tensile force can reduce the ATII cell membrane tension so as to inhibit the infection efficiency of the SARS-CoV-2 pseudovirus on ATII cells, and an important theoretical basis is provided for clarification of a mechanical regulation mechanism of respiratory virus invasion.
Absstract of: CN122325619A
The invention discloses a novel coronavirus tandem multi-epitope protein, a nanoparticle vaccine as well as a preparation method and application thereof, and belongs to the technical field of preparation of novel coronavirus vaccines. Aiming at a novel coronavirus epidemic strain, T cell and B cell epitope prediction is carried out on a core protein coded by the novel coronavirus epidemic strain, and the novel coronavirus conservative dominant antigen epitope is obtained through screening. On the basis of conservative dominant antigen epitopes of the new coronavirus, multi-epitope display is carried out by adopting a tandem expression strategy, meanwhile, a SpyTag sequence is designed at the C end of a tandem multi-epitope sequence, a T cell helper epitope PADRE protein sequence is designed at the N end of the tandem multi-epitope sequence, and the novel coronavirus multi-epitope nanoparticle vaccine is constructed by taking AP205 VLP as a carrier. The vaccine can induce an organism to generate a high-titer specific antibody, effectively prevents infection of various novel coronavirus epidemic strains, and shows a good application prospect in pathogen prevention and control.
Absstract of: CN122326601A
The invention discloses antisense oligonucleotide for targeted inhibition of an RdRp gene and application of the antisense oligonucleotide. According to the research, a series of antisense oligonucleotides (ASO) are designed and screened aiming at a highly conservative target spot of SARS-CoV-2 RNA dependent RNA polymerase (RdRp), and the antiviral effect of the antisense oligonucleotides on various new coronavirus variants is systematically evaluated. Experimental results show that the designed ASO molecule, especially RDRP-5-, shows significant virus inhibition ability in a plurality of experimental levels (including a reporter gene system, a virus replicon model and a true virus infection experiment).
Absstract of: US20260183385A1
0000 Provided are a vaccine composition for pan-COVID-19 comprising a consensus sequence of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) variants.
Absstract of: WO2026141623A1
Provided is an antiviral drug that is effective against SARS-CoV-2. Provided are: a compound represented by formula (I) (in the formula, Ar and R are as defined in the specification); a salt thereof; a solvate of these; a prodrug of these; and an anti-SARS-CoV-2 drug comprising these.
Nº publicación: WO2026139703A1 02/07/2026
Applicant:
PECSI TUDOMANYEGYETEM [HU]
DEBRECENI EGYETEM [HU]
DEBRECENI EGYETEM
P\u00C9CSI TUDOM\u00C1NYEGYETEM
Absstract of: WO2026139703A1
The present invention relates to compounds for use in the treatment of a disease or condition caused by Zika virus, Dengue virus, West Nile virus, Chikungunya virus, O`nyong`nyong virus, Sindbis virus or SARS-CoV-2 virus.
BOPI
Electronic site
